These results further confirmed the potential of the 4‐ERLR‐based score in predicting the suitability of immune checkpoint blockade in ccRCC patients, and the high sensitivity of anti‐PD1 immunotherapy and anti‐CTLA4 immunotherapy in ccRCC patients with high‐risk group. The gene discussed is CTLA4; the disease is nonpapillary renal cell carcinoma.